After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making ...

Dr Ricardo Sainz-Fuertes is global director of digital health solutions at Eisai, Co. He is a psychiatrist, neuroscientist, ...

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections.

For example, take IMU technologies, geo-positioning, and actigraphy, which can now be used to monitor movement and gross ...

Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer ...

Nexpovio (selinexor) – which is sold as Xpovio in some markets – is a first-in-class nuclear export XPO1 inhibitor that was ...

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for ...

The PM Society is a not-for-profit organisation with 40 years of Giving Back. Often, we have not shouted about the ...

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK ...

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the ...

Myrbetriq – sold as Betanis and Betmiga in some markets – is an extended-release selective beta3-adrenoceptor agonist therapy ...

The EC’s concern was that Vifor Pharma – which was acquired by CSL in an $11.7 billion deal a few months after the probe was ...